<DOC>
	<DOCNO>NCT01990261</DOCNO>
	<brief_summary>This study evaluate survival non-small cell lung cancer ( wild-type EGFR ) participant treat Tarceva least one fail chemotherapy treatment , impact prior chemotherapy treatment .</brief_summary>
	<brief_title>A Study Assess Survival Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adults &gt; /= 18 year Histologically document locally advanced , metastatic , recurrent nonsmall cell lung carcinoma wildtype EGFR eligible Tarceva treatment . At least one fail chemotherapy treatment . Unknown EGFR mutation status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>